Pharma stocks including Ajanta Pharma, Sun Pharmaceutical Industries, and Lupin were buzzing in trade as investor focus sharpened ahead of Novo Nordisk A/S’s blockbuster weight‑loss drug semaglutide losing patent protection in India. The key patent for semaglutide, the active ingredient in Ozempic and Wegovy, which transformed the global weight‑loss and diabetes treatment landscape, is set to expire in India on March 21, 2026, paving the way for cheaper generic launches. At least five Indian drugmakers, including Mankind Pharma, Ajanta Pharma, Sun Pharma, and Lupin, have indicated readiness to roll out generic versions immediately after expiry through statements and post‑earnings commentary, Bloomberg reported.
